Eledon Pharmaceuticals, Inc. (ELDN) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 19, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Eledon Pharmaceuticals, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Eledon Pharmaceuticals, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Eledon Pharmaceuticals, Inc. actually do?
Answer:
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing tegoprubart, an anti-CD40L antibody, for organ transplant rejection and amyotrophic lateral sclerosis (ALS). Tegoprubart is engineered to target the CD40 Ligand pathway, aiming to provide improved safety and efficacy over existing anti-CD40 approaches by blocking co-stimulatory signaling and promoting a tolerogenic environment. The company is prioritizing kidney transplantation programs, having completed Phase 2 trials and planning for a potential Phase 3 study. Eledon is also exploring xenotransplantation and has investigated tegoprubart for islet cell transplantation and ALS, though further financing is needed for the ALS program. The company does not own manufacturing facilities and relies on third-party providers for production.
Question:
What are Eledon Pharmaceuticals, Inc.'s revenue drivers?
Answer:
The company has not generated any revenue from product sales to date. Future revenue is expected to be driven by the successful development and commercialization of tegoprubart.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required